Alembic Pharma gets USFDA nod for generic version of Glycopyrrolate injection

Glycopyrrolate injection is also indicated for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated, the company said. As per IQVIA data, Alembic said Glycopyrrolate injection had an estimated market size of USD 42 million for the 12 months ended June 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZElXjxN
via IFTTT